Ballicules.com

Carbidopa/ levodopa ER

RYTARY

What it isExtended-release levodopa replacement paired with carbidopa’s peripheral AADC inhibition; Parkinson disease.

Why this oneIt combines immediate- and extended-release beads to smooth motor fluctuations and reduce "off" time in Parkinson disease; it is not interchangeable mg-for-mg with IR Sinemet.

What limits itDyskinesia, nausea, orthostasis, and hallucinations can limit use; conversion from other levodopa products requires retitration.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Parkinson's disease / parkinsonism (levodopa-naive)Adults23.75 mg/95 mg TID x3 days36.25 mg/145 mg TID (day 4); up to 97.5 mg/390 mg TID612.5 mg/2,450 mg per day
Parkinson's disease (converting from IR carbidopa-levodopa)AdultsPer conversion table (Table 1)Individualized, 3-5 times daily612.5 mg/2,450 mg per day

Renal Undefined

Hepatic Undefined

Dosing frequency may be increased from TID up to 5 times daily; not interchangeable 1:1 with other carbidopa-levodopa products

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No adequate human data; animal studies show developmental toxicity including teratogenicity — may cause fetal harm

Lactation Levodopa detected in human milk; may inhibit lactation (decreases prolactin); consider benefits vs risk

NO BOXED WARNINGS

Principal riskDyskinesia and motor fluctuation with cumulative exposure

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Carbidopa/ levodopa ER ballicule

Carbidopa/ levodopa ER ballicule: receptor binding, kinetics and half-life diagram

Open Carbidopa/ levodopa ER in the interactive console ↗

Memory aids: mascots and interaction avatars

Carbidopa/ levodopa ER SINEMET mascot mnemonic cartoon
“(Carly and Levi) Dopey Cinema”
Carbidopa/ levodopa ER Box: minimal PK interactions avatar
Box: minimal PK interactions

Open Carbidopa/ levodopa ER in the interactive console ↗